BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

MacuSight, Inc. 

32980 Alvarado-Niles Road
Suite 846
Union City  California  94587  U.S.A.
Phone: 510-400-1440 Fax: 510-400-1441


SEARCH JOBS


Industry
Pharmaceutical

Segment
Start Up





 Company News
MacuSight, Inc. Receives Fast Track Designation From FDA for Perceiva(TM) in Treatment of Diabetic Macular Edema 10/21/2009 9:46:26 AM    More...
MacuSight, Inc. Provides Clinical Development Update for Perceiva(TM) Four Phase 2 Clinical Trials in Major Ocular Diseases Fully Enrolled; Data Available in First Half of 2010 9/30/2009 10:37:43 AM    More...
etrials Chosen by MacuSight, Inc. as its EDC and IVR Solutions Provider On Three Ophthalmology Studies 4/16/2009 8:39:55 AM    More...
MacuSight, Inc. Appoints Gerald Wroblewski Vice President of Operations Move Adds Key Manufacturing Expertise as Company Broadly Advances Sirolimus Clinical Development 11/6/2008 10:59:29 AM    More...
Santen Pharmaceutical and MacuSight, Inc. Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions; MacuSight to Receive Upfront $50 Million 6/2/2008 8:59:24 AM    More...
MacuSight, Inc. Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration Sirolimus Demonstrates Favorable Safety Profile and Improvements in Visual Acuity 2/25/2008 7:42:28 AM    More...
MacuSight, Inc. Expands Management Team With Appointment of Dr. Joel Naor as Chief Medical Officer 2/20/2008 9:01:41 AM    More...
MacuSight, Inc. Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema 10/1/2007 8:38:49 AM    More...
MacuSight, Inc. Appoints Brian C. Cunningham To Board Of Directors 11/2/2006 11:12:49 AM    More...
MacuSight, Inc. Initiates Wet Age-Related Macular Degeneration Study 10/31/2006 11:13:21 AM    More...
12

//-->